Kenvue Inc.

NYSE KVUE

Kenvue Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 29, 2024: 21.26%

Kenvue Inc. EBITDA Margin is 21.26% for the Trailing 12 Months (TTM) ending September 29, 2024, a -5.67% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Kenvue Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 22.54%, a -2.93% change year over year.
  • Kenvue Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending October 02, 2022 was 23.22%.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
NYSE: KVUE

Kenvue Inc.

CEO Mr. Thibaut Mongon
IPO Date May 4, 2023
Location United States
Headquarters 199 Grandview Road
Employees 22,000
Sector Consumer Staples
Industries
Consumer Packaged Goods Cosmetics Personal Care
Description

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

StockViz Staff

January 15, 2025

Any question? Send us an email